Показано 0 из 0
Дата |
---|
18.03.2024 |
15.03.2024 |
14.03.2024 |
13.03.2024 |
12.03.2024 |
11.03.2024 |
08.03.2024 |
07.03.2024 |
06.03.2024 |
05.03.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.311
|
0.3399
|
0.3121
|
0.2787
|
0.3498
|
0.319
|
|
|
781 463.66
|
4 495.00
|
0.35
|
0.351
|
0.2774
|
0.2712
|
0.3888
|
0.3478
|
|
|
7 516 427.31
|
36 842.00
|
4.92
|
5.00
|
4.95
|
4.935
|
4.99
|
4.99
|
|
|
1 322 633.61
|
1 433.00
|
4.93
|
4.96
|
4.93
|
4.93
|
4.9799
|
4.95
|
|
|
577 346.73
|
714.00
|
4.94
|
4.96
|
4.94
|
4.92
|
4.97
|
4.95
|
|
|
1 034 752.86
|
1 472.00
|
4.91
|
4.95
|
4.96
|
4.91
|
4.975
|
4.92
|
|
|
846 250.40
|
823.00
|
4.91
|
4.94
|
4.92
|
4.90
|
4.96
|
4.93
|
|
|
2 008 661.10
|
1 480.00
|
4.87
|
4.90
|
4.90
|
4.89
|
4.92
|
4.90
|
|
|
2 434 182.10
|
1 682.00
|
4.91
|
4.93
|
4.89
|
4.89
|
4.95
|
4.94
|
|
|
854 655.82
|
1 267.00
|
4.89
|
4.92
|
4.88
|
4.88
|
4.925
|
4.92
|
|
|
1 332 668.94
|
1 784.00
|
LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets.